EA200100937A1 - Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов - Google Patents

Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов

Info

Publication number
EA200100937A1
EA200100937A1 EA200100937A EA200100937A EA200100937A1 EA 200100937 A1 EA200100937 A1 EA 200100937A1 EA 200100937 A EA200100937 A EA 200100937A EA 200100937 A EA200100937 A EA 200100937A EA 200100937 A1 EA200100937 A1 EA 200100937A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
compositions
methods
inhibitors
antagonists
Prior art date
Application number
EA200100937A
Other languages
English (en)
Inventor
Пол Д. Рубин
Тимоти Дж. Барберич
Original Assignee
Сепракор Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сепракор Инк. filed Critical Сепракор Инк.
Publication of EA200100937A1 publication Critical patent/EA200100937A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

Настоящее изобретение относится к способам и композициям для профилактики, лечения и возможности справляться с нарушениями желудочно-кишечного тракта или их симптомами с использованием двух или более агентов или соединений, которые обеспечивают трехсайтное действие на 5-НТ-рецепторы, на 5-НТ-рецепторы и, по меньшей мере, на один из антагонистов H-рецепторов и ингибиторов протонных насосов.Отчет о международном поиске был опубликован 2001.09.07.
EA200100937A 1999-03-02 2000-03-01 Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов EA200100937A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12239399P 1999-03-02 1999-03-02
PCT/US2000/005167 WO2000051584A2 (en) 1999-03-02 2000-03-01 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Publications (1)

Publication Number Publication Date
EA200100937A1 true EA200100937A1 (ru) 2002-10-31

Family

ID=22402453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100937A EA200100937A1 (ru) 1999-03-02 2000-03-01 Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов

Country Status (21)

Country Link
US (2) US6362202B1 (ru)
EP (1) EP1156853A2 (ru)
JP (1) JP2002538104A (ru)
KR (1) KR20010108299A (ru)
CN (1) CN1399572A (ru)
AR (1) AR022811A1 (ru)
AU (1) AU3710800A (ru)
BG (1) BG105932A (ru)
BR (1) BR0008664A (ru)
CA (1) CA2362488A1 (ru)
CO (1) CO5150222A1 (ru)
EA (1) EA200100937A1 (ru)
EE (1) EE200100459A (ru)
HU (1) HUP0200151A3 (ru)
IL (1) IL145163A0 (ru)
NO (1) NO20014229L (ru)
NZ (1) NZ513967A (ru)
PL (1) PL350862A1 (ru)
SK (1) SK12342001A3 (ru)
TR (1) TR200103128T2 (ru)
WO (1) WO2000051584A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1347779A2 (en) * 2000-11-24 2003-10-01 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004024192A1 (en) * 2002-09-12 2004-03-25 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
SE0203410D0 (sv) * 2002-11-18 2002-11-18 Astrazeneca Ab New use
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
EP1567163B1 (en) * 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
WO2004089414A2 (en) * 2003-04-08 2004-10-21 Medley S.A. Indústria Farmacêutica Combinations of proton pump inhibitors or blockers with prokinetic agents
EP1663313A2 (en) * 2003-08-29 2006-06-07 Dynogen Pharmaceuticals Inc. Compositions useful for treating gastrointestinal motility disorders
WO2006011159A2 (en) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
WO2006026337A1 (en) * 2004-08-25 2006-03-09 Fairfield Clinical Trials, Llc Combination of a proton pump inhibitor and a h2 antagonist for the treatment of gastroesophageal reflux disease
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7730891B2 (en) * 2005-10-07 2010-06-08 Lamberg Steven B Intraoral mandibular advancement device for treatment of sleep disorders
US20070079833A1 (en) * 2005-10-07 2007-04-12 Lamberg Steven B Intraoral mandibular advancement device for treatment of sleep disorders, including snoring, obstructive sleep apnea, and gastroesophageal reflux disease and method for delivering the same
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US20080234703A1 (en) * 2007-03-23 2008-09-25 Ethicon Endo-Surgery, Inc. Tissue approximation system
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5914460B2 (ja) 1978-12-27 1984-04-04 相互薬工株式会社 Ｈ↓２受容体「きつ」抗剤シメチジンの製造法
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SI8710091A8 (en) 1987-01-23 1996-06-30 Lek Tovarna Farmacevtskih Process for obtaining crystalline cimetadine (n-cyano-n'-methyl-n"- (2/(5-methyl-1h-imidazole-4-yl)methylthio/ethyl)-guanidine
IT1215344B (it) 1987-01-27 1990-02-08 Dessy S R L Ora Recordati Farm Procedimento per la preparazione di composti ad attivita' anti-ulcera.
JPH0623180B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
JPH0623181B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ATE170747T1 (de) 1991-12-21 1998-09-15 Smithkline Beecham Plc Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP1145715A3 (en) 1992-07-07 2004-05-19 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08502031A (ja) 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
WO1995001803A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5502195A (en) 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5541335A (en) 1994-07-11 1996-07-30 Torcan Chemical Ltd. Process for preparing nizatidine
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ATE251139T1 (de) * 1997-07-11 2003-10-15 Janssen Pharmaceutica Nv (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
ES2237117T3 (es) * 1998-06-15 2005-07-16 Sepracor Inc. Uso de (-)norcisaprida opticamente pura en el tratamiento del sindrome del intestino irritable.
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists

Also Published As

Publication number Publication date
CN1399572A (zh) 2003-02-26
SK12342001A3 (sk) 2002-01-07
AR022811A1 (es) 2002-09-04
EE200100459A (et) 2002-12-16
PL350862A1 (en) 2003-02-10
CO5150222A1 (es) 2002-04-29
US6548518B2 (en) 2003-04-15
US20020086881A1 (en) 2002-07-04
WO2000051584A3 (en) 2001-09-07
NO20014229L (no) 2001-11-01
NO20014229D0 (no) 2001-08-31
TR200103128T2 (tr) 2002-03-21
KR20010108299A (ko) 2001-12-07
NZ513967A (en) 2001-09-28
US6362202B1 (en) 2002-03-26
AU3710800A (en) 2000-09-21
BR0008664A (pt) 2001-12-18
HUP0200151A3 (en) 2003-09-29
CA2362488A1 (en) 2000-09-08
HUP0200151A2 (en) 2002-06-29
WO2000051584A2 (en) 2000-09-08
JP2002538104A (ja) 2002-11-12
IL145163A0 (en) 2002-06-30
BG105932A (en) 2002-12-29
EP1156853A2 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
EA200100936A1 (ru) Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
CY1105299T1 (el) Χρηση των επιλεκτικων αγωνιστων του υποδοχεα 4 (ep4) προσταγλανδινης (pge2) για τη θepαπεια της οξειας και χρονιας νεφρικης ανεπαρκειας
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
EA200300387A1 (ru) Ингибиторы рецептора ep4 для лечения ревматоидного артрита
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
SE0100172D0 (sv) New inhibitors against galectins
DE602004027021D1 (de) Cgrp-rezeptorantagonisten
ATE503755T1 (de) Cgrp-rezeptorantagonisten
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6